← Leaderboards
Yong Zang
Indiana University Indianapolis
$1,237,789
Attributed
$1,237,789
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $320.2K · FY2021–25$500K$375K$250K$125K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,237,789 · 2
By mechanism
R01$960,741 · 1
R21$277,048 · 1
Top collaborators
No co-investigators on record.
Most similar at Indiana University Indianapolis
Same institution · by research overlap
- Shannon L Risacher$4,683,456
- Jeffrey Dage$4,494,717
- Bradford C Dickerson$59,157,479
- Gil Dan Rabinovici$42,270,973
Others in their field
Other Emerging Leaders on “Complex”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Chanza Baytop · Westat, Inc.$271,217,917
- Leonard Freedman · Leidos Biomedical Research, Inc.$58,784,651
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$41,535,815
- John Hobbs · Suny At Stony Brook$41,239,084
Research focus
ComplexPerformanceResponseWeb AppTrial DesignClinical PracticeLikelihood FunctionsPhysiciansTherapeutic EffectUser-FriendlyDimensionsDoseToxic EffectSeriesAlgorithmsFlexibilityMonitorBiomarker EvaluationBiological Response Modifier TherapyAdvocateBackBig DataAccelerationBenefits And Risks
Grant awards (5)
Use Bayesian methods to facilitate the data integration for complex clinical trials$320,247
R01 · FY2025 · GM · contact PI
Use Bayesian methods to facilitate the data integration for complex clinical trials$320,247
R01 · FY2024 · GM · contact PI
Use Bayesian methods to facilitate the data integration for complex clinical trials$320,247
R01 · FY2023 · GM · contact PI
Curve-free phase I/II clinical trial designs for molecularly targeted agents and immunotherapy$137,004
R21 · FY2022 · CA · contact PI
Curve-free phase I/II clinical trial designs for molecularly targeted agents and immunotherapy$140,044
R21 · FY2021 · CA · contact PI